Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Bepirovirsen in Renal Impairment (B-Kind)
NCT07168356Phase 1Active, not recruiting
- Sponsor
- GSK
- Start
- Sep 2025
- Primary completion
- Mar 2026
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, open-label trial of bepirovirsen in hepatitis B (HBV) (3 arms), sponsored by GSK. Primary endpoints: Plasma Area Under the Concentration Time Curve From Time Zero Extrapolated to Infinite Time at Day 50 and Maximum Observed Concentration at Day 50. Started Sep 2025; status: active, not recruiting.
02
Drugs
bepirovirsen
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT07168356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07168356.